Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for patients with CD19(+) B-cell malignancies. Combination strategies that improve CAR T-cell potency, limit tumor environment–mediated immune dysfunction, and directly reduce tumor burden may increase the potential for durable...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother
Päätekijät: Qin, Jim S., Johnstone, Timothy G., Baturevych, Alex, Hause, Ronald J., Ragan, Seamus P., Clouser, Christopher R., Jones, Jon C., Ponce, Rafael, Krejsa, Cecile M., Salmon, Ruth A., Ports, Michael O.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Lippincott Williams & Wilkins 2020
Aiheet:
Basic Studies
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7144752/
https://ncbi.nlm.nih.gov/pubmed/31899702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000307
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia